The FDA expanded Gilead’s Trodelvy label to allow use as a first-line treatment for triple-negative breast cancer regardless of PD-L1 status, strengthening the company’s position in the fast-growing TROP2 antibody-drug conjugate (ADC) space. The update comes less than a month after a separate front-line TNBC approval for AstraZeneca and Daiichi’s Datroway. Gilead’s new label supports Trodelvy either alone for patients not eligible for PD-1/L1 inhibitors or in combination with Merck’s Keytruda for PD-L1-positive tumors (combined positive score ≥10). The approval is supported by results from two phase 3 trials: Ascent-03 for PD-(L)1 ineligible patients and Ascent-04 (Keynote-D19) for PD-L1-positive disease. The commercial impact is immediate: prescribers now have a broader first-line option anchored in clinical evidence across PD-L1 strata, intensifying pricing and sequencing pressure across competing ADC programs. Rivals including Datroway’s ongoing development will face an additional standard-of-care benchmark. The FDA decision also keeps the market war over TNBC ADC leadership active while combination dynamics—especially those involving Keytruda—continue to determine how broadly each agent can be positioned in real-world treatment pathways.